Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer

Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer

Conditions: Adenocarcinoma of the Pancreas; Stage III Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: leucovorin calcium; Drug: fluorouracil; Drug: nelfinavir mesylate; Radiation: stereotactic body radiation therapy; Radiation: hypofractionated radiation therapy; Procedure: therapeutic conventional surgery
Sponsors: University of Nebraska; National Cancer Institute (NCI)
Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 11, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments